The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM plus and CNS plus Mature B-NHL: A Children's Oncology Group Report

被引：0
|
作者：
Goldman, Stanton [1 ]
Galardy, Paul J. [2 ]
Smith, Lynette [3 ]
Perkins, Sherrie L. [4 ,5 ]
Shiramizu, Bruce [6 ]
Gross, Thomas [7 ]
Sanger, Warren G. [8 ]
Harrison, Lauren [9 ]
Cairo, Mitchell S. [9 ]
机构：
[1] Med City Childrens, Dallas, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Nebraska Med Ctr, COPH Biostat, Omaha, NE USA
[4] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[5] ARUP Labs, Salt Lake City, UT USA
[6] Univ Hawaii, Honolulu, HI 96822 USA
[7] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[8] Univ Nebraska, Med Ctr, Human Genet Lab, Omaha, NE USA
[9] New York Med Coll, Valhalla, NY 10595 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1161 / 1162
页数：2
相关论文
共 47 条
  • [1] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] OUTCOME AND PATTERNS OF FAILURE FOLLOWING COMBINED FAB CHEMOTHERAPY AND RITUXIMAB IN CHILDREN AND ADOLESCENTS WITH STAGE III/IV, BM+ AND/OR CNS+ MATURE B-NHL: A CHILDREN'S ONCOLOGY REPORT
    Goldman, S.
    Smith, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Harrison, L.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 176 - 176
  • [3] THE EFFICACY OF RASBURICASE DURING REDUCTION COP CHEMOTHERAPY FOR THE PREVENTION OF TUMOR LYSIS SYNDROME (TLS) IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED STAGE III/IV, BM+ AND CNS+ MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Hochberg, Jessica
    Galardy, Paul
    Goldman, Stanton
    Smith, Lynette
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2012, 58 (07) : 1041 - 1041
  • [4] Safety and pharmacokinetics of rituximab in combination with FAB chemotherapy in children and adolescents with Stage III/IV mature B-NHL and B-cell leukemia ± CNS disease: a Children's Oncology Group Report
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 23 - 23
  • [5] The efficacy of rasburicase during COP reduction for the prevention of TLS in children and adolescents with newly diagnosed advanced stage mature B-NHL: a Children's Oncology Group report
    Hochberg, J. C.
    Galardy, P. J.
    Goldman, S.
    Perkins, S.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 26 - 26
  • [6] SAFETY AND PHARMACOKINETICS (PK) OF RITUXIMAB (R) IN COMBINATION WITH FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS (C+A) WITH STAGE III/IV MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 112 - 112
  • [7] RESULTS OF THE ADDITION OF RASBURICASE(RU) AND RITUXMAB(RM) TO THE FAB/LMB96 CHEMOTHERAPY BACKBONE IN CHILDREN plus ADOLESCENTS(C plus A) WITH MATURE B-NHL:A CHILDREN'S ONCOLOGY GROUP REPORT
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    Perkins, Sherrie
    Sanger, Warren
    Gross, Thomas
    Shiramizu, Bruce
    Goldman, Stanton
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 858 - 858
  • [8] Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 24 - 24
  • [9] Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab plus FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    van de Ven, Carmella
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Goldman, Stanton
    BLOOD, 2008, 112 (11) : 310 - 310
  • [10] OUTCOME AND PHARMACOKINETIC (PK) ANALYSIS OF ADDING RITUXIMAB TO FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH ADVANCED MATURE B-NHL/LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP REPORT
    Goldman, Stan
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 737 - 738
12345